BJH - volume 10, issue 5, september 2019
T. Feys MBA, MSc
EHA 2019 featured several eagerly awaited presentations on Hodgkin lymphoma (HL). This included 3-year follow-up data of the ECHELON-1 trial in patients with high-risk features and longer follow-up data of CheckMate 2015 evaluating nivolumab plus doxorubicin, vinblastine, and dacarbazine in newly diagnosed advanced HL. In a third interesting HL abstract it was shown that foregoing radiotherapy in PET-negative patients with early-stage HL increases the risk of disease progression. In non-Hodgkin lymphoma (NHL), data were presented indicating that there is no benefit of rituximab maintenance beyond two years in patients with relapsed or refractory indolent NHL. In addition to this, interesting data were presented on the use of an obinutuzumab + DHAP combination in patients with untreated mantle cell lymphoma, with polatuzumab vedotin + obinutuzumab + lenalidomide in relapsed/refractory follicular lymphoma (FL) and with the anti-CD47 antibody Hu5F9-G4 in patients with refractory lymphoma.
(BELG J HEMATOL 2019;10(5):208–13)
Read moreBJH - volume 10, issue 5, september 2019
T. Feys MBA, MSc
OVERVIEW OF BELGIAN REIMBURSEMENT NEWS
(BELG J HEMATOL 2019;10(5):224)
Read moreBJH - volume 10, issue 3, may 2019
T. Feys MBA, MSc
OVERVIEW OF BELGIAN REIMBURSEMENT NEWS
(BELG J HEMATOL 2019;10(3):130–1)
Read moreBJH - volume 10, issue 2, march 2019
T. Feys MBA, MSc
OVERVIEW OF BELGIAN REIMBURSEMENT NEWS
(BELG J HEMATOL 2019;10(2):96–7)
Read moreBJH - volume 10, issue 1, february 2019
T. Feys MBA, MSc
The introduction of targeted agents revolutionized the care for patients with chronic lymphocytic leukemia (CLL). While these agents first proved their clinical benefit in the treatment of patients with relapsed/refractory (R/R) disease and in CLL patients with dismal prognostic features (e.g. del(17p), TP53 mutations) they were subsequently also tested in the first-line setting and in patients without high-risk cytogenetic characteristics. During the 2018 annual meeting of the American Society of Hematology (ASH), results were presented of several pivotal trials that will likely change the frontline treatment paradigm for CLL patients. A second hot topic in CLL that received lots of attention at ASH 2018 consists of minimal residual disease (MRD). Several studies were presented looking into the feasibility of obtaining a MRD negative status with (combinations of) novel targeted agents in CLL and look into the prognostic significance of obtaining MRD negativity. Finally, R/R disease continues to be the setting in which novel therapeutic options are being tested. During ASH 2018 results of several clinical trials evaluating combinations of existing targeted agents were presented in addition to data on completely new therapeutics (e.g. chimeric antigen receptor [CAR] T cell therapy) that try to make their mark in CLL. This article will summarize some of the key highlights in CLL presented at ASH 2018.
(BELG J HEMATOL 2019;10(1):11–7)
Read moreBJH - volume 10, issue 1, february 2019
T. Feys MBA, MSc
With respect to chronic myeloid leukemia (CML), the 2018 annual meeting of the American Society of Hematology featured the following sessions: The CML educational session, 3 oral sessions with 6 abstract presentations each, and a long list of posters. This report will briefly summarize the key messages from the educational session discussing the choice of first-line treatment in CML patients. The highlights from the oral and poster sessions will be grouped in three categories: new drugs in CML, treatment-free remission (TFR) and CML and pregnancy.
(BELG J HEMATOL 2019;10(1):31–5)
Read moreBJH - volume 10, issue 1, february 2019
T. Feys MBA, MSc
This article will summarize the key studies in the field of lymphoma presented at the 2018 annual meeting of the American Society of Hematology (ASH). The selected abstracts include updates in Hodgkin lymphoma (HL), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL) and mantle cell lymphoma (MCL). We would like to thank Dr. Christophe Bonnet (CHU de Liège) for his help in selecting the most relevant lymphoma abstracts from the ASH program.
(BELG J HEMATOL 2019;10(1):41–8)
Read more
Top
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
